Account wins from the 06/06/06 News Brief

Share this article:
Seidler Bernstein is developing an international marketing and communications program for Dako’s Serum HER-2/neu, a biomarker assay for metastatic breast cancer assessment. Seidler Bernstein's Dako account creative team will include Jennifer Vaughan, account manager; Alla Litovchenko, senior designer; and Rob Kinslow, copywriter. GSW Worldwide has been named agency of record for telavancin in the United States.  Telavancin is a lipoglycopeptide injectable antibiotic currently in Phase 3 studies for the treatment of complicated skin and skin structure infections and hospital-acquired pneumonia. Discovered by Theravance, telavancin is being co-developed worldwide with Astellas Pharma. Once approved by the FDA, GSW Worldwide will provide a broad range of strategic marketing and promotional services for telavancin in the US. The account will be based in GSW Worldwide's Columbus office. Duramed Pharmaceuticals has retained Pace, part of Lowe Healthcare Worldwide, as consumer and professional agency for the relaunch of ParaGard (intrauterine copper contraceptive). Duramed acquired ParaGard when it bought FEI Women's Health last year for $281.5 million. MBL Communications has appointed independent media representative company Sherburne Medical Media to represent various accounts for the publications CNS Spectrums and Primary Psychiatry and for Psychiatry Weekly.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.